Clinical efficacy of rosuvastatin, amiodarone and warfarin in combination in treatment of paroxysmal atrial fibrillation

Objective To analyze the clinical effect of rosuvastatin, amiodarone and warfarin in combination in the treatment of patients with paroxysmal atrial fibrillation. Methods A total of 80 patients with paroxysmal atrial fibrillation were selected and randomly divided into control group(n=40)and treatment group(n=40). The left ventricular ejection fraction and serum N-terminal cerebral titanium precursor levels were compared between the two groups before and after treatment. The changes of left atrial diameter before and 3, 6 months after treatment were compared between the two groups, and the maintenance rates of sinus rhythm after treatment of two groups were calculated. The occurrence of adverse reactions in two groups was recorded. Results After treatment, compared with the controlgroup, the left ventricular ejection fraction of the treatment group was significantly higher, the serum N-terminal brain titanium precursor level was significantly lower than that in the treatment group(P<0.05). Compared with the control group, the values of left atrial inner diameter at 3 and 6 months after treatment of the treatment group were significantly larger(P<0.05). The maintenance rate of sinus rhythm showed a significant difference in the two groups(P<0.05). The incidence of adverse reactions was 7.50%, which was significantly lower than 25.00% of the control group(P<0.05). Conclusion Rosuvastatin, amiodarone and warfarin in combination in the treatment of patients with paroxysmal atrial fibrillation can significantly improve their cardiac function and promote recovery.